U.et al (2013)
Its current program specifics are posted on Medvi's official website
Health Care System In March, the Congressional Budget Office (CBO) predicted that covering GLP-1 weight loss drugs at their current prices, would cost the federal government more than it would save from reducing other health care spending. In August, a study published in the Annals of Internal Medicine by researchers from Brigham and Womens Hospital, found that if Medicare Part D coverage for high-priced GLP-1 weight loss drugs expanded for new classifications such as cardiovascular disease, it could cost the U.S
Thangaraj A, Chivero ET, Tripathi A, Singh S, Niu F, Guo ML, et al
Cancer Cell 40 (4), 365378 e366
Retatrutide is an investigational medicine that isnt licensed by the MHRA in the UK as of May 2026